Evaluating the Additional Advantages of Botulinum Toxin Type A in Combination or Sequential Treatment Approaches for Scar Management: A Systematic Review and Meta-Analysis
-
By
-
Yunfei Ma
-
Wanming Qu
-
June 11, 2026
Clinical Report: Evaluating the Additional Advantages of Botulinum Toxin Type A in Combination or Sequential Treatment Approaches for Scar Management
Overview
This systematic review and meta-analysis evaluates the efficacy of botulinum toxin type A (BoNT-A) as an adjunctive treatment in scar management. The findings suggest that BoNT-A may significantly improve scar appearance, although the evidence is of low certainty.
Background
Scarring is a common consequence of wound healing that can lead to functional impairment and psychological distress. Various treatment modalities exist, but outcomes are often variable, prompting the use of multimodal strategies. BoNT-A has emerged as a potential adjunctive therapy aimed at reducing mechanical tension on healing wounds, which is a key factor in pathological scar formation.
Data Highlights
| Outcome Measure | Mean Difference (MD) |
|---|---|
| Vancouver Scar Scale (VSS) | -1.80 |
| Stony Brook Scar Evaluation Scale (SBSES) | 1.46 |
Key Findings
- BoNT-A significantly improved scar appearance with a MD of -1.80 for VSS.
- BoNT-A showed a MD of 1.46 for SBSES, indicating improved scar evaluation.
- The evidence supporting BoNT-A's efficacy is classified as low-certainty.
- Mechanical tension is a recognized contributor to pathological scar formation.
- BoNT-A may facilitate more favorable scar maturation by reducing local muscle activity.
Clinical Implications
Clinicians should consider the potential adjunctive benefits of BoNT-A in scar management, particularly in cases where mechanical tension is a concern. However, treatment plans should remain individualized and cautious due to the low-certainty evidence.
Conclusion
While BoNT-A may offer benefits in scar management, further high-quality, standardized randomized controlled trials are necessary to confirm these findings.
Related Resources & Content
- Frontiers in Psychiatry, 2026 -- Beyond aesthetic outcomes: psychodermatological benefits of botulinum toxin treatment in the upper facial third. A narrative review
- Clinical Rheumatology, 2024 -- A comprehensive review of the efficacy of botulinum toxin in managing Raynaud's phenomenon associated with scleroderma
- Hernia, 2021 -- A comprehensive review and meta-analysis of the technical considerations and clinical outcomes associated with botulinum toxin administration before abdominal wall reconstruction
- Management of Keloids and Hypertrophic Scars | AAFP, 2024
- Effectiveness of Botulinum Toxin-A on Face, Head, and Neck Scars: A Systematic Review and Meta-Analysis, 2024
- Efficacy of triamcinolone acetonide combined with botulinum toxin A in the treatment of hypertrophic scars and keloids: A meta-analysis, 2024
- Evaluating the Dose-Dependent Efficacy of Botulinum Toxin Injections in Managing Chronic Anal Fissures: A Meta-Analytic Review
- Management of Keloids and Hypertrophic Scars | AAFP
- Effectiveness of Botulinum Toxin-A on Face, Head, and Neck Scars: A Systematic Review and Meta-Analysis - Almoaidbellah Rammal, Ahmed Mogharbel, 2024
- Efficacy of triamcinolone acetonide combined with botulinum toxin A in the treatment of hypertrophic scars and keloids: A meta-analysis - ScienceDirect
Based on findings from:
Add-on benefits of botulinum toxin type A in combination or sequential therapies for scar management: a systematic review and meta-analysis
Yunfei Ma, Wanming Qu. Frontiers In Pain Research, 2026.
https://www.frontiersin.org/journals/pain-research/articles/10.3389/fpain.2026.1844493/full
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
